NYSE - Delayed Quote
USD
Stevanato Group S.p.A. (STVN)
17.06
+0.55
(+3.33%)
At close: June 17 at 4:00:03 PM EDT
Trade STVN on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for STVN
- Previous Close
16.51 - Open
16.53 - Bid 16.85 x 30000
- Ask 26.15 x 60000
- Day's Range
16.50 - 17.69 - 52 Week Range
12.89 - 28.00 - Volume
334,621 - Avg. Volume
524,474 - Market Cap (intraday)
4.657B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
28.92 - EPS (TTM)
0.59 - Earnings Date (est.) Aug 4, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.85
Recent News
View More
Performance Overview
Trailing total returns as of 6/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
STVN
14.90%
S&P 500 (^GSPC)
8.39%
1-Year Return
STVN
28.96%
S&P 500 (^GSPC)
24.03%
3-Year Return
STVN
46.81%
S&P 500 (^GSPC)
68.27%
5-Year Return
STVN
2.46%
S&P 500 (^GSPC)
75.75%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/17/2026
-
Market Cap
4.66B
-
Enterprise Value
5.05B
-
Trailing P/E
28.86
-
Forward P/E
19.46
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
3.34
-
Price/Book (mrq)
2.63
-
Enterprise Value/Revenue
3.61
-
Enterprise Value/EBITDA
14.89
Financial Highlights
Profitability and Income Statement
-
Profit Margin
11.75%
-
Return on Assets (ttm)
5.27%
-
Return on Equity (ttm)
9.59%
-
Revenue (ttm)
1.2B
-
Net Income Avi to Common (ttm)
141.35M
-
Diluted EPS (ttm)
0.59
Balance Sheet and Cash Flow
-
Total Cash (mrq)
112.28M
-
Total Debt/Equity (mrq)
29.43%
-
Levered Free Cash Flow (ttm)
-57.06M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
323.59
-1.82%
Mkt Cap
22.861B
Industry
Medical Instruments & Supplies
24.86
+0.44%
Mkt Cap
4.045B
Industry
Medical Instruments & Supplies
161.20
-8.76%
Mkt Cap
EUR
15.681B
Industry
Medical Instruments & Supplies
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Dropping Coverage of Stevanato
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice Target -
Stevanato's Sturdy Growth Shows No Signs of Slowing as Q2 Exceeds Forecasts; Shares Fairly Valued
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice Target -
Stevanato Starts Year With Solid Q1, Sturdy Switching Costs Support Its Moat; Shares Undervalued
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice Target -
Stevanato Starts Year With Solid Q1, Sturdy Switching Costs Support Its Moat; Shares Undervalued
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice Target
